Publication | Open Access

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Dose-escalation StudyCell TherapyNovel TherapyMedicineImmunologyGene EditingGenome EditingCell BiologyCrisprImmune Cell TherapyImmunotherapyOncologyCell TransplantationPhase 1Tumor MicroenvironmentRefractory T-cell Malignancies